Uquifa and chemistry

Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of SONEAS, a Budapest (Hungary) headquartered CDMO company, focussed on the Innovator Pharmaceutical and Fine Chemical sectors. The business has been acquired from Lochlomond and Euroventures which are both based out of Hungary. SONEAS has for the year 2017, reported revenues of €12.2mn.

The acquisition broadens UQUIFA´s market offering in the CDMO space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development. These projects can then also potentially feed into UQUIFA´s existing cGMP inspected and approved manufacturing facilities in Spain and Mexico, creating a high-value project pipeline.

About SONEAS

SONEAS, established in 1996, with a team strength of 144 people, is a Budapest, Hungary headquartered firm with business verticals focused on R+D and CMO, targeted at the Innovator Pharma and Fine Chemical sectors.In R+D, it is a professional chemical service provider with research and analytical labs across two operating sites in Budapest. It also has an 8,000 sq mtr facility which houses process R+D, kilo lab and a cGMP approved pilot plant facility which was commissioned in 2002. In CMO, it is operating on 65,000 m2 site and capable of providing starting materials, intermediates for pharma and non-pharma applications as well as other fine chemical products on a commercial scale. SONEAS existing customer base includes names like Chinoin, Ogeda, Eisai, Leo Pharma among others.

For further information on SONEAS, visit www.soneas.com

The UQUIFA Group (www.uquifa.com) is a Barcelona headquartered small-molecule API (active pharmaceutical ingredient) development and manufacturing enterprise. Founded in 1936, the UQUIFA Group today, caters to a global customer base from its sites in Spain, Mexico and Hungary across the CDMO and Off-Patent API business lines. It is focused on delivering value through its development & manufacturing capabilities to a customer base across the pharmaceutical and specialty chemical industries with the USA, EU and Japan being its principal markets. 

Soneas, a Budapest-based company focused on CDMO activities, is also a part of the UQUIFA group since 2018. We offer route scouting, process optimisation, small scale cGMP manufacturing, large scale non-GMP manufacturing from 3 locations in Budapest.

1 location in Spain and 1 in Mexico and +20 certificates of suitability gives us geographical spread with +40 Type II DMF's filed with the FDA and more than 150 active DMF's Worldwide

Barcelona, Spain

• Main office
• Located in Passeig de Gràcia
• CEO central functions
• 38 administration and management personnel

Sant Celoni, Spain

• High tech site with main R+D centre for APIs and CMO
• Total capacity of 155m3
• FDA last inspection May'17
• c-GMP, Korean FDA (2011), Jap-Cert, ANVISA

Cuernavaca, Mexico

• R+D centre for APIs and CMO
• Competitive manufacturing base
• Total capacity 200m3
• FDA last inspection 2018
• CGMP, ANVISA

Soneas, Hungary

• Soneas is a company focused on custom development and synthesis of fine chemicals and active ingredients used for application in the pharmaceutical, specialty chemical & crop protection industries
• Located In Budapest with R&D Labs, GMP Pilot plant and a large-scale manufacturing site
• With access to proprietary technologies which add value to the customer´s project, Soneas is an ideal partner for your development & manufacturing needs

We strive to meet maximun quality standards, continuous improving development processes and respecting legislation and the environment.

UQUIFA believes one of the keys to sustainable success is to always act within the law by meeting all ethical principes in today's society.